Aelis Farma Announces the Recruitment of the First Patient for the Phase 1/2 Clinical Trial of Its Drug Candidate AEF0217 for the Treatment of Cognitive Disorders in Down Syndrome

Aelis Farma Announces the Recruitment of the First Patient for the Phase 1/2 Clinical Trial of Its Drug Candidate AEF0217 for the Treatment of Cognitive Disorders in Down Syndrome
CANNANNEW REPORT

The trial should include around 45 participants with Down syndrome (trisomy 21) and should be completed in the second quarter of 2023 BORDEAUX, France–(BUSINESS WIRE)–Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, announces today the recruitment of the first […]

Excerpt only …
READ MORE BELOW
Source : Aelis Farma Announces the Recruitment of the First Patient for the Phase 1/2 Clinical Trial of Its Drug Candidate AEF0217 for the Treatment of Cognitive Disorders in Down Syndrome

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.